Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 2,100 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable saline Clear all
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

NCT02683941
View directory record Official record
Conditions
Neuroendocrine Tumors in Lung
Interventions
Lanreotide (Autogel formulation), Placebo, Best Supportive Care
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 30, 2026, 6:27 AM EDT
Terminated Phase 4 Interventional

Pain Management After Total Shoulder Arthroplasty

NCT03219983
View directory record Official record
Conditions
Glenohumeral Arthritis, Total Shoulder Arthroplasty
Interventions
Ropivacaine, liposomal bupivacaine
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 30, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine

NCT04078022
View directory record Official record
Conditions
Shigella
Interventions
SF2a-TT15 Shigella Vaccine, Placebo, S. flexneri 2a strain 2457T Challenge Agent
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 30, 2026, 6:27 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza

NCT02927431
View directory record Official record
Conditions
Virus Diseases
Interventions
Danirixin 15 mg FBE, Danirixin 50 mg FBE, Placebo, Oseltamivir 75 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Stamford, Connecticut • Council Bluffs, Iowa • Natchitoches, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 30, 2026, 6:27 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

GnRH Agonist at Embryo Transfer: IVF Outcomes

NCT03544073
View directory record Official record
Conditions
Infertility, Infertility, Female, Infertility, Male
Interventions
Saline Solution for Injection, Leuprolide Acetate
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 30, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 30, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy

NCT02762929
View directory record Official record
Conditions
Postoperative Pain, Bunions
Interventions
HTX-011A, Saline Placebo, HTX-011B, HTX-002, Bupivacaine HCl, HTX-009
Drug · Biological
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Anaheim, California • Bakersfield, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 30, 2026, 6:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery

NCT02498769
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Joseph Mathew, M.D.
Other
Eligibility
50 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 30, 2026, 6:27 AM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety Study of TPX-115 on Partial-thickness Rotator Cuff Tear

NCT07219654
View directory record Official record
Conditions
Partial Thickness Rotator Cuff Tears
Interventions
TPX-115, Cryopreserving hyaluronic acid medium, Saline
Biological · Other · Drug
Lead sponsor
Tego Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
La Mesa, California • Deerfield Beach, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 30, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

NCT04129931
View directory record Official record
Conditions
Asthma
Interventions
MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
29
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 30, 2026, 6:27 AM EDT
Terminated Phase 4 Interventional Results available

Becker Continued Access Study

NCT01286870
View directory record Official record
Conditions
Breast Reconstruction
Interventions
Mentor Becker 25 Expander/Breast Implant, Mentor Becker 50 Expander/Breast Implant
Device
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 30, 2026, 6:27 AM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma

NCT03927222
View directory record Official record
Conditions
Glioblastoma
Interventions
Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF, Temozolomide, Tetanus-Diphtheria Toxoid (Td), GM-CSF, 111-Indium-labeling of Cells for in vivo Trafficking Studies
Biological · Drug
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 30, 2026, 6:27 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence

NCT00758420
View directory record Official record
Conditions
Varicose Veins
Interventions
Varisolve (Polidocanol Endovenous Microfoam), Agitated Saline
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Scottsdale, Arizona • New York, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 30, 2026, 6:27 AM EDT
Completed Not applicable Interventional

Dexmedetomidine After Cesarean for the Treatment of Nausea and Shivering

NCT03370562
View directory record Official record
Conditions
Shivering, Nausea and Vomiting, Postoperative
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 30, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

NCT00985673
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A, Seasonal trivalent influenza vaccine (TIV), Saline placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 40 Years
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Stockbridge, Georgia • Raleigh, North Carolina • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 30, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 30, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

NCT01482221
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD6765 iv, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Chino, California • Lond Beach, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 30, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

Anticholinergic vs. Botox Comparison Study

NCT01166438
View directory record Official record
Conditions
Urge Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg, Trospium chloride
Drug
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 30, 2026, 6:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol

NCT01618916
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY3015014, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Honolulu, Hawaii • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 30, 2026, 6:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa

NCT00063778
View directory record Official record
Conditions
HIV Infections
Interventions
AVX101, placebo
Biological · Other
Lead sponsor
AlphaVax, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Oct 30, 2026, 6:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

NCT05805826
View directory record Official record
Conditions
Clostridoides Difficile Associated Disease
Interventions
C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2., C. difficile vaccine formulation 3., Saline Placebo.
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
936 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
23
States / cities
Phoenix, Arizona • Anaheim, California • Doral, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 30, 2026, 6:27 AM EDT
Not yet recruiting Phase 3 Interventional

Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity

NCT07021937
View directory record Official record
Conditions
Obesity/Therapy
Interventions
Semaglutide 1.7mg subcutaneous, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 30, 2026, 6:27 AM EDT
Recruiting Phase 2 Interventional

Y-90 Treatment Response Using Transarterial Radioembolization

NCT07145801
View directory record Official record
Conditions
HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions
Lumason, Sonazoid
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 30, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

NCT02316470
View directory record Official record
Conditions
Clostridium Difficile
Interventions
VLA84, Placebo
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
50 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
7
States / cities
Huntsville, Alabama • Chula Vista, California • La Mesa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 30, 2026, 6:27 AM EDT